Profil
Thomas H.
Grove worked as Secretary, Chief Technology Officer & EVP at Careside, Inc. from 1996 to 2001.
He also worked as Vice President-Product Development at ProteoGenix, Inc. and as President & Chief Technology Officer at Biocentrex LLC.
Grove holds a doctorate degree from Syracuse University and an undergraduate degree from The State University of New York.
Anciens postes connus de Thomas H. Grove
| Sociétés | Poste | Fin |
|---|---|---|
ProteoGenix, Inc.
 ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | Corporate Officer/Principal | 29/03/2012 |
Careside, Inc.
 Careside, Inc. Medical SpecialtiesHealth Technology Careside, Inc. develops and sells a proprietary blood testing systems. The Careside system consists of the Careside Analyzer and disposable test cartridges, the H-2000 and Careside connect. The Careside Analyzer is easy to use and can be operated by a non-technical person with appropriate training in connection with use of the device. Its software will enable the user to capture all data required to comply with the clinical laboratory improvement. The company was founded in July 1996 and is headquartered in Culver City, CA. | Directeur Technique/Scientifique/R&D | 01/01/2001 |
| Biocentrex LLC | President | - |
Formation de Thomas H. Grove
| The State University of New York | Undergraduate Degree |
| Syracuse University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
ProteoGenix, Inc.
ProteoGenix, Inc. Medical SpecialtiesHealth Technology ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy. | Health Technology |
| Biocentrex LLC | |
Careside, Inc.
Careside, Inc. Medical SpecialtiesHealth Technology Careside, Inc. develops and sells a proprietary blood testing systems. The Careside system consists of the Careside Analyzer and disposable test cartridges, the H-2000 and Careside connect. The Careside Analyzer is easy to use and can be operated by a non-technical person with appropriate training in connection with use of the device. Its software will enable the user to capture all data required to comply with the clinical laboratory improvement. The company was founded in July 1996 and is headquartered in Culver City, CA. | Health Technology |
